[1] 崔海伦, 任汝静, 王刚. 帕金森病及帕金森叠加综合征神经影像学诊断价值及研究进展[J]. 中国现代神经疾病杂志, 2018,18(4):231-237.
[2] 王刚, 吕发金. 痴呆及相关认知障碍的神经影像学诊断流程建议[J]. 重庆医科大学学报,2017,42(6):684-686.
[3] Manyam BV.What is and what is not 'Fahr's disease'[J]. Parkinsonism Relat Disord,2005,11(2):73-80.
[4] 黄越, 陈生弟, Gregor Wenning, 等. 非典型性帕金森样病[J]. 中国现代神经疾病杂志,2011,11(1):7-14.
[5] 崔诗爽, 陈生弟, 王刚. 非酮症性高血糖伴偏侧舞蹈症一例[J]. 中华神经科杂志,2017,50(1):54-55,56.
[6] Massey LA, Jäger HR, Paviour DC, et al.The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy[J]. Neurology,2013,80(20):1856-1861.
[7] Yoon RG, Kim SJ, Kim HS, et al.The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography[J]. Neurosci Lett,2015,584:296-301.
[8] Wang Y, Butros SR, Shuai X, et al.Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging[J]. Am J Neuroradiol, 2012,33(2):266-273.
[9] 金莉蓉, 黄振. 帕金森病磁共振成像研究进展[J]. 重庆医科大学学报, 2017,42(6):662-666.
[10] Madhyastha TM, Askren MK, Boord P, et al.Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease[J]. Mov Disord,2015, 30(14):1893-1900.
[11] Teune LK, Renken RJ, de Jong BM, et al. Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET ima-ging[J]. Neuroimage Clin,2014,5:240-244.
[12] Melzer T, Watts R, MacAskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease[J]. Brain,2011,134(Pt 3):845-855.
[13] Deng XY, Wang L, Yang TT, et al.A meta-analysis of diffusion tensor imaging of substantia nigra in patients with Parkinson's disease[J]. Sci Rep,2018,8(1):2941.
[14] 邢一兰, 陈俊抛, 苏欢欢. 磁共振弥散张量成像在帕金森病早期诊断以及定量分析中的临床应用价值[J]. 中国现代医学杂志, 2015,25(8):43-46.
[15] Vaillancourt DE, Spraker MB, Prodoehl J, et al.High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease[J]. Neurology,2009,72(16):1378-1384.
[16] Du G, Lewis MM, Sen S, et al.Imaging nigral pathology and clinical progression in Parkinson's disease[J]. Mov Disord,2012,27(13):1636-1643.
[17] Prakash BD, Sitoh YY, Tan LC, et al.Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease[J]. Parkinsonism Relat Disord,2012,18(9):1029-1033.
[18] Vaillancourt DE, Spraker MB, Prodoehl J, et al.High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease[J]. Neurology,2009,72(16):1378-1384.
[19] Gao LL, Wu T.The study of brain functional connectivity in Parkinson's disease[J]. Transl Neurodegener,2016, 5:18.
[20] Zang YF, He Y, Zhu CZ, et al.Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI[J]. Brain Dev,2007,29(2):83-91.
[21] Zang Y, Jiang T, Lu Y, et al.Regional homogeneity approach to fMRI data analysis[J]. Neuroimage,2004,22(1):394-400.
[22] Díez-Cirarda M, Strafella AP, Kim J, et al.Dynamic functional connectivity in Parkinson's disease patients with mild cognitive impairment and normal cognition[J]. Neuroimage Clin, 2018,17:847-855.
[23] 梅明金, 聂坤, 熊冬生, 等. 帕金森病多模态磁共振成像和基于图论的复杂网络分析法研究进展[J]. 中国现代神经疾病杂志,2017,17(1):14-17.
[24] Ciurleo R, Bonanno L, Di Lorenzo G, et al.Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study[J]. Neurosci Lett,2015,599:55-60.
[25] Guan J, Rong Y, Wen Y, et al.Detection and application of neurochemical profile by multiple regional (1)H-MRS in Parkinson's disease[J]. Brain Behav,2017,7(9):e00792.
[26] Federico F, Simone IL, Lucivero V, et al.Proton magne-tic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders[J]. Mov Disord,1997,12(6):903-909.
[27] Gröger A, Bender B, Wurster I, et al.Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging[J]. J Neurol Neurosurg Psychiatry,2013,84(6):644-649.
[28] Zanigni S, Testa C, Calandra-Buonaura G, et al.The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes[J]. Parkinsonism Relat Disord, 2015, 21(8):929-937.
[29] Yamamoto H, Arimura S, Nakanishi A, et al.Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT[J]. Ann Nucl Med, 2017, 31(5):407-412.
[30] Yoshii F, Ryo M, Baba Y, et al.Combined use of dopamine transporter imaging (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease[J]. J Neurol Sci,2017, 375:80-85.
[31] Berg D, Behnke S, Seppi K, et al.Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease[J]. Mov Disord,2013,28(2):216-219.
[32] Berg D,Godau J, Walter U.Transcranial sonography in movement disorders[J]. Lancet Neurol,2008,7(11):1044-1055.
[33] Iranzo A, Stockner H, Serradell M, et al.Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder[J]. Mov Disord, 2014,29(14):1774-1780.
[34] Li DH, He YC, Liu J, et al.Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis[J]. Sci Rep,2016,6:20863.
[35] Walter U, Dressler D, Probst T, et al.Transcranial brain sonography findings in discriminating between parkinso-nism and idiopathic Parkinson disease[J]. Arch Neurol,2007,64(11):1635-1640.
[36] Giannoccaro MP, Donadio V, Incensi A, et al.Skin biopsy and I-123 MIBG scintigraphy findings in idiopathic Parkinson's disease and parkinsonism: a comparative study[J]. Mov Disord,2015,30(7):986-989.
[37] Mochizuki H, Ebihara Y, Ugawa Y, et al.PR Prolongation and Cardiac 123I-MIBG Uptake Reduction in Parkinson's Disease[J]. Eur Neurol,2015,74(1-2):107-111.
[38] Sakakibara R, Tateno F, et al.MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review[J]. Parkinsonism Relat Disord,2014,20(3):267-273
[39] Nicastro N, Burkhard PR, Garibotto V.Scan without evidence of dopaminergic deficit(SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: A prospective study[J]. J Neurol Sci,2018,385:17-21.
[40] Erro R, Bhatia KP.Novel movement disorder society-Parkinson's disease criteria: What about SWEDD and genetic forms?[J]. Mov Disord,2016,31(3):431.
